Abstract
Drugs used to treat cancer may affect the skeleton in several ways, the most important being a decrease in sex steroid levels. This may induce rapid bone loss. Tamoxifen is a partial oestrogen receptor agonist and antagonist (classified as a selective oestrogen receptor modulator or SERM). As it has agonistic effects on oestrogen receptors of bone it increases bone mineral density and thus may potentially prevent fractures. In contrast aromatase inhibitors such as anastrozole lead to a decrease in bone mineral density and an increased risk of fractures. Most high-dose intravenous chemotherapeutic regimens induce rapid bone loss from effects on the gonads with induction, for example, of premature menopause. Low-dose oral agents such as methotrexate are not associated with an increased risk of fractures. Androgen deprivation therapies such as LHRH agonists in breast cancer are also associated with an increase in bone loss and an increased risk of fractures. With the increasing long-term survival of patients with cancer, preventive measures against osteoporosis must be considered.
Keywords: Skeletal Effects of Drugs, Cancer, sex steroid levels, Tamoxifen, bone mineral density, aromatase inhibitors, osteoporosis, antagonist
Current Drug Safety
Title: Skeletal Effects of Drugs to Treat Cancer
Volume: 3 Issue: 3
Author(s): Peter Vestergaard
Affiliation:
Keywords: Skeletal Effects of Drugs, Cancer, sex steroid levels, Tamoxifen, bone mineral density, aromatase inhibitors, osteoporosis, antagonist
Abstract: Drugs used to treat cancer may affect the skeleton in several ways, the most important being a decrease in sex steroid levels. This may induce rapid bone loss. Tamoxifen is a partial oestrogen receptor agonist and antagonist (classified as a selective oestrogen receptor modulator or SERM). As it has agonistic effects on oestrogen receptors of bone it increases bone mineral density and thus may potentially prevent fractures. In contrast aromatase inhibitors such as anastrozole lead to a decrease in bone mineral density and an increased risk of fractures. Most high-dose intravenous chemotherapeutic regimens induce rapid bone loss from effects on the gonads with induction, for example, of premature menopause. Low-dose oral agents such as methotrexate are not associated with an increased risk of fractures. Androgen deprivation therapies such as LHRH agonists in breast cancer are also associated with an increase in bone loss and an increased risk of fractures. With the increasing long-term survival of patients with cancer, preventive measures against osteoporosis must be considered.
Export Options
About this article
Cite this article as:
Vestergaard Peter, Skeletal Effects of Drugs to Treat Cancer, Current Drug Safety 2008; 3 (3) . https://dx.doi.org/10.2174/157488608785699522
DOI https://dx.doi.org/10.2174/157488608785699522 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design of Magnetic Nanoparticles-Assisted Drug Delivery System
Current Pharmaceutical Design Cellular Uptake and Organ Accumulation of Amphipolar Metallocorroles with Cytoprotective and Cytotoxic Properties
Anti-Cancer Agents in Medicinal Chemistry Surface Modification of Nanocarriers for Cancer Therapy
Current Nanoscience Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Rapid Biosynthesis of Gold Nanoparticles Using Aqueous-ethanoic Leaf Extract of Heartleaf Moonseed: Characterization and Effect of pH on its Synthesis
Current Nanomaterials Recent Approaches in Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal The Ambivalent Role of Apoptosis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Pharmaceutical Design Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
Current Medicinal Chemistry Lectins in Human Cancer: Both a Devil and an Angel?
Current Protein & Peptide Science MicroRNAs and Cancer Therapy – From Bystanders to Major Players
Current Medicinal Chemistry Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy
Current Drug Safety Recent Technological Advances in the Mass Spectrometry-based Nanomedicine Studies: An Insight from Nanoproteomics
Current Pharmaceutical Design Cyclometalated Complexes of Platinum and Gold with Biological Properties: State-of-the-Art and Future Perspectives
Current Medicinal Chemistry Withdrawal Notice: Recent Developments in Anti-Cancer Activity of Compounds Containing the Thioether Group
Anti-Cancer Agents in Medicinal Chemistry Choosing between Targeted Therapies for Rheumatoid Arthritis Patients: The Oncology Perspective
Current Rheumatology Reviews PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development
Current Drug Targets Small Molecule CXCR4 Chemokine Receptor Antagonists: Developing Drug Candidates
Current Medicinal Chemistry